1.8.07: Specialty Pharmaceuticals Report
A roundtable forum, an analyst and top management from 7 firms examine the Specialty Pharmaceuticals sector in this 48 page report from The Wall Street Transcript.

  1. Roundtable forum: Deb Knobelman, Piper Jaffray & Co.; Angela Larson, Susquehanna Financial Group; Robert Uhl, Friedman, Billings, Ramsey Group, Inc.

  2. Small Cap Specialty Pharmaceuticals: Timothy Chiang, FTN Midwest Securities Corp.

  3. CEO Interviews (average 2,500 words): Top management from 7 sector firms examine the outlook for their firm and sector. Firms interviewed include: BioSante Pharmaceuticals, Inc., Axcan Pharma Inc., Bradley Pharmaceuticals, Inc., Callisto Pharmaceuticals, Inc., CollaGenex Pharmaceuticals, Inc., Provectus Pharmaceuticals, Inc. and Skystar Bio-Pharmaceutical Co.

    Topics covered: The outlook for generics - Patent challenges - The legality of authorized generics - Management performance - Options and earnings restatements - Partnerships with Big Pharma - Legal and regulatory outlook - The FDA approval process - New product pipelines - M&A activity - Stock recommendations - Stocks to avoid - Investor interest 

    Companies covered: Pharmion (PHRM), Penwest Pharmaceuticals (PPCO), DURECT (DRRX), Akorn (AKN), CollaGenex (CGPI), Barr Pharmaceuticals (BRL), Elan (ELN), Salix (SLXP), Santarus (SNTS), Endo Pharmaceuticals (ENDP), Connetics (CNCT), Teva (TEVA), Sepracor (SEPR), Sciele (SCRX), Noven (NOVN), Barrier (BTRX), KV (KVA) and Watson Pharmaceuticals (WPI).
    ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us

    For immediate access online - click here to gain a password.  

    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
           		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

 

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.


Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE